BOSTON, May 27, 2020 (GLOBE NEWSWIRE) — Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a virtual fireside chat at the Jefferies 2020 Healthcare Conference on Wednesday, June 3, 2020, at 3:00 p.m. ET.
To access the live webcast presentation, or the subsequent archived recording, please visit the “Investors” section of the Ziopharm website at www.ziopharm.com.About Ziopharm Oncology, Inc.
Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharm’s pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more information, please visit www.ziopharm.comInvestor Relations Contacts:
Ziopharm Oncology:
Chris Taylor
VP, Investor Relations and Corporate Communications
T: 617.502.1881
E: ctaylor@ziopharm.comLifeSci Advisors:
Mike Moyer
Managing Director
T: 617.308.4306
E: mmoyer@lifesciadvisors.comMedia Relations Contact:
LifeSci Communications:
Patrick Bursey
T: 646.876.4932
E: pbursey@lifescicomms.com
Bay Street News